NCT04353102View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 22, 2020

Primary Completion Date

September 14, 2021

Study Completion Date

November 24, 2021

Conditions

Advanced Solid Malignancies

Interventions

DRUG

YH002

YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.

Trial Locations (3)

2162

Macquarie University, Macquarie

2217

St George Private Hospital, Kogarah

3199

Peninsula & South Eastern Haematology and Oncology Group, Frankston

All Listed Sponsors

lead

Eucure (Beijing) Biopharma Co., Ltd

INDUSTRY

NCT04353102 - A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter